"The acceleration of the inclusion of new drugs in medical insurance reflects the support of the national medical insurance policy for innovative drugs, and more new drugs will benefit patients in the future." On February 28, a number of industry insiders told the people's ** health client reporter.
According to the official website of the National Health Insurance Administration, in recent years, the drugs included in the medical insurance catalogue are mainly new drugs approved within 5 years, and the waiting time for new drugs to be included in the medical insurance catalogue has been shortened from an average of nearly 5 years in the past to less than 2 years. Taking the 2022 NRDL as an example, 105 of the 108 new negotiated and bidding drugs were marketed after January 1, 2017, accounting for 97%. Some new drugs have been included in the medical insurance catalogue only half a year after they were launched. Medicare spending on new drugs increased from 59 in 20194.9 billion yuan, an increase to 481 in 20228.9 billion yuan, an increase of 71 times.
According to the Blue Book on the Progress and Effectiveness of Medical Insurance Drug Management Reform released by the Chinese Pharmaceutical Association and the China Medical Insurance Research Association, the time from the listing of new drugs to the drug catalog has been significantly shortened. "China Medical Security" ** Figure.
Wang Guang, director of the endocrinology department of Beijing Chaoyang Hospital, pointed out in an interview with the reporter of the people's health client that most of the drugs newly included in the medical insurance catalogue are newly listed in recent years and have high clinical value, especially the drugs with new mechanisms and new targets.
In the matter of including new drugs in medical insurance and supporting innovative drugs, the National Health Insurance Administration has always taken "patient benefit" as the premise. In the above reply, the National Health Insurance Administration stated that it adheres to the "value purchase", determines the best level of benefits brought by drugs to patients, and better serves the vast number of insured people, so that patients can use innovative drugs with better efficacy with more reasonable results. At the same time, from the perspective of considering safety, the National Health Insurance Bureau inspects the use of drugs every 2 years, and adjusts the payment standards according to the actual sales of drugs.
On the other hand, the support of medical insurance policies for new drugs has also promoted the transformation and acceleration of innovative drug achievements. Deng Zhidong, general manager of Hainan Boao Medical Technology, said in an interview with the People's Health client that in the past, new drugs could not be included in the scope of reimbursement in time after approval, which inhibited the transformation momentum of domestic innovative drugs to a certain extent. Nowadays, the dynamic adjustment of the medical insurance catalogue is quickly and effectively incorporated into the urgent clinical needs, giving innovative drugs the opportunity to be included in the national medical insurance reimbursement as soon as possible after they are launched: "With the further standardization of the drug use and dynamic adjustment of China's medical insurance catalogue, this will be conducive to improving the efficiency of the use of medical insurance funds." From the perspective of the pharmaceutical industry, it is conducive to promoting the innovation and development of medicine. ”